was read the article
array:23 [ "pii" => "S0301054616301562" "issn" => "03010546" "doi" => "10.1016/j.aller.2016.10.003" "estado" => "S300" "fechaPublicacion" => "2017-03-01" "aid" => "818" "copyright" => "SEICAP" "copyrightAnyo" => "2016" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Allergol Immunopathol (Madr). 2017;45:115-20" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 92 "formatos" => array:3 [ "EPUB" => 4 "HTML" => 37 "PDF" => 51 ] ] "itemSiguiente" => array:18 [ "pii" => "S0301054616300672" "issn" => "03010546" "doi" => "10.1016/j.aller.2016.04.005" "estado" => "S300" "fechaPublicacion" => "2017-03-01" "aid" => "765" "copyright" => "SEICAP" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Allergol Immunopathol (Madr). 2017;45:121-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 109 "formatos" => array:3 [ "EPUB" => 1 "HTML" => 26 "PDF" => 82 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Comparison of two diagnostic techniques, skin-prick test and component resolved diagnosis in the follow-up of a cohort of paediatric patients with pollinosis. Multicentre pilot study in a highly exposed allergenic area" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "121" "paginaFinal" => "126" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E. González-Mancebo, J. Domínguez-Ortega, S. Blanco-Bermejo, E. González-Seco, M.J. Trujillo, F. de la Torre" "autores" => array:7 [ 0 => array:2 [ "nombre" => "E." "apellidos" => "González-Mancebo" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Domínguez-Ortega" ] 2 => array:2 [ "nombre" => "S." "apellidos" => "Blanco-Bermejo" ] 3 => array:2 [ "nombre" => "E." "apellidos" => "González-Seco" ] 4 => array:2 [ "nombre" => "M.J." "apellidos" => "Trujillo" ] 5 => array:2 [ "nombre" => "F." "apellidos" => "de la Torre" ] 6 => array:1 [ "colaborador" => "on behalf of the ESPLORA Group" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0301054616300672?idApp=UINPBA00004N" "url" => "/03010546/0000004500000002/v1_201702200044/S0301054616300672/v1_201702200044/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0301054616301665" "issn" => "03010546" "doi" => "10.1016/j.aller.2016.10.013" "estado" => "S300" "fechaPublicacion" => "2017-03-01" "aid" => "828" "copyright" => "SEICAP" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Allergol Immunopathol (Madr). 2017;45:105-14" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 142 "formatos" => array:3 [ "EPUB" => 2 "HTML" => 32 "PDF" => 108 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Global Asthma Network survey suggests more national asthma strategies could reduce burden of asthma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "105" "paginaFinal" => "114" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1942 "Ancho" => 3333 "Tamanyo" => 515012 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Countries asthma strategy.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "I. Asher, T. Haahtela, O. Selroos, P. Ellwood, E. Ellwood" "autores" => array:6 [ 0 => array:2 [ "nombre" => "I." "apellidos" => "Asher" ] 1 => array:2 [ "nombre" => "T." "apellidos" => "Haahtela" ] 2 => array:2 [ "nombre" => "O." "apellidos" => "Selroos" ] 3 => array:2 [ "nombre" => "P." "apellidos" => "Ellwood" ] 4 => array:2 [ "nombre" => "E." "apellidos" => "Ellwood" ] 5 => array:1 [ "colaborador" => "the Global Asthma Network Study Group" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0301054616301665?idApp=UINPBA00004N" "url" => "/03010546/0000004500000002/v1_201702200044/S0301054616301665/v1_201702200044/en/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "The effect of nebulised magnesium sulphate in the management of childhood moderate asthma exacerbations as adjuvant treatment" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "115" "paginaFinal" => "120" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "S. Turker, M. Dogru, F. Yildiz, S. Bozkaya Yilmaz" "autores" => array:4 [ 0 => array:2 [ "nombre" => "S." "apellidos" => "Turker" ] 1 => array:4 [ "nombre" => "M." "apellidos" => "Dogru" "email" => array:1 [ 0 => "mdmahmut@yahoo.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 2 => array:2 [ "nombre" => "F." "apellidos" => "Yildiz" ] 3 => array:2 [ "nombre" => "S. Bozkaya" "apellidos" => "Yilmaz" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Zeynep Kamil Woman and Children's Diseases Training and Research Hospital, Department of Pediatrics, Istanbul, Turkey" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1181 "Ancho" => 1463 "Tamanyo" => 88838 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">The change of MPIS between the two groups with respect to time.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Asthma, which is common all over the world, is a chronic respiratory disease affecting 1–18% of the population in different countries. Exacerbations of asthma are episodes characterised by a progressive increase in symptoms of shortness of breath, cough, wheezing or chest tightness and progressive decrease in lung function. Severe exacerbations can be potentially life-threatening, and require early evaluation and careful follow-up. The main characteristic of asthma exacerbation is airflow obstruction in the respiratory tract. The aim of treatment is to rapidly relieve airflow obstruction and hypoxaemia, address the underlying inflammatory pathophysiology, and prevent relapse. Oxygen, short-acting beta<span class="elsevierStyleInf">2</span>-agonist (SABA), and systemic corticosteroids (oral/iv) are used in the first step of treatment of asthma exacerbation in the emergency department. In patients who do not respond to initial treatment; ipratropium bromide, aminophylline or theophylline, IV magnesium, helium and high dose inhaled corticosteroid treatments are applied.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Magnesium plays a role as a co-factor in more than 300 enzymatic reactions, including in particular, glycolysis and oxidative phosphorylation. Magnesium is accepted as the physiological antagonist of calcium.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">2</span></a> In addition to these functions, magnesium has also bronchodilatory and anti-inflammatory effects.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">2–6</span></a> The mechanism of bronchodilation consists in making dose-dependent relaxation in bronchial smooth muscle.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">3</span></a> The inhibition of histamine from mast cells, acetylcholine from cholinergic nerve terminals and the release of calcium into the cytoplasm play a role in this formation.<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">4–7</span></a> In children, the anti-inflammatory and bronchodilatory effect of magnesium is promising as an adjuvant treatment for patients who do not respond to treatment in severe asthma exacerbation. In GINA 2015, intravenous magnesium sulphate (MgSO(4)) treatment is not recommended for routine use in acute asthma exacerbations. However, it has been reported that the application of 2<span class="elsevierStyleHsp" style=""></span>g magnesium as a single dose within 20<span class="elsevierStyleHsp" style=""></span>min intravenous infusion reduces hospitalisation in adult patients with FEV1 <25–30% at admission to hospital, in adult and paediatric patients who fail to respond to initial treatment and have persistent hypoxaemia, and in paediatric patients who do not reach FEV1 60% predicted after 1<span class="elsevierStyleHsp" style=""></span>h of care.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">1</span></a> Cochrane meta-analysis reported no signs of evidence that inhaled MgSO(4) can be used as a substitute for inhaled SABA. While this drug is used in addition to inhaled SABA (with or without inhaled ipratropium), no overall clear evidence for improved pulmonary function or reduced hospital admissions are stated.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">8</span></a> Studies investigating the usage of Mg in asthmatic children are rare.<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">9–12</span></a> In these studies, mostly mild to moderate or moderate-to-severe asthmatic children were evaluated. This study has aimed to investigate the clinical findings and the effects of hospitalisation of nebulised isotonic Mg given in addition to standard asthma exacerbation treatment in children who come to the emergency room with moderate asthma exacerbations.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Study design</span><p id="par0015" class="elsevierStylePara elsevierViewall">Our study population included 100 consecutive children whose age ranged between 3 and 15 years with asthma and who admitted to the emergency department due to moderate asthma exacerbations between February 2014 and September 2014. This study was designed as randomised controlled double-blind. Before starting the study, the ethical approval of Zeynep Kamil Woman and Children's Diseases Training and Research Hospital was taken and also the aim and procedures of the study were explained to children and their families and their verbal and written approval was taken. The study adhered to the principles of Helsinki Declaration.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Study population</span><p id="par0020" class="elsevierStylePara elsevierViewall">Patients were asked to fill in a questionnaire during the first assessment. This questionnaire included the following: the demographic characteristics of patients, whether they used preventive medicine or not, if they used how long and in which dose, the presence of upper respiratory tract infection symptoms before exacerbations, whether they took salbutamol and/or inhaled corticosteroids at home, the number of exacerbations in the last one year and the number of hospitalisations, history of atopy, and whether cigarettes are smoked at home. Those patients are included in the study: patients over three years old being followed-up in paediatric allergy clinic with the diagnosis of asthma, and children admitted to the emergency department due to moderate asthma exacerbations.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">1</span></a> Patients with any associated chronic diseases such as cystic fibrosis, bronchiectasis were excluded from this study.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Study interventions</span><p id="par0025" class="elsevierStylePara elsevierViewall">The 100 patients were randomised to placebo or magnesium, with 50 patients in each arm. The patients selected for the magnesium group received nebulised salbutamol (0.15<span class="elsevierStyleHsp" style=""></span>mg/kg/dose) and 1<span class="elsevierStyleHsp" style=""></span>ml magnesium sulphate (15%)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>1.5<span class="elsevierStyleHsp" style=""></span>ml isotonic saline on three occasions at roughly 20<span class="elsevierStyleHsp" style=""></span>min intervals, and 1<span class="elsevierStyleHsp" style=""></span>mg/kg methylprednisolone IV with the first dose of treatments applied. For those patients who did not respond adequately, nebulised salbutamol treatment was continued, on three occasions at roughly 40<span class="elsevierStyleHsp" style=""></span>min intervals.</p><p id="par0030" class="elsevierStylePara elsevierViewall">The patients selected for the placebo group received nebulised salbutamol (0.15<span class="elsevierStyleHsp" style=""></span>mg/kg/dose) and 2.5<span class="elsevierStyleHsp" style=""></span>ml isotonic saline mixture on three occasions at roughly 20<span class="elsevierStyleHsp" style=""></span>min intervals, and 1<span class="elsevierStyleHsp" style=""></span>mg/kg methylprednisolone IV with the first dose treatments applied. For those patients who did not respond adequately, nebulised salbutamol treatment was continued three times with 40<span class="elsevierStyleHsp" style=""></span>min intervals (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Clinical evaluation</span><p id="par0035" class="elsevierStylePara elsevierViewall">Modified Pulmoner Index Score (MPIS) was used in the clinical evaluation of patients. In the MPIS, six categories are evaluated: oxygen saturation, accessory muscle use, inspiratory to expiratory flow ratio, degree of wheezing, heart rate, and respiratory rate. For each of these six measurements or observations, a score of 0–3 is assigned per each.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">13</span></a> In all patients, at 0th, 20th, 40th, 120th and if necessary 200th min, the response to the treatment was evaluated by MPIS. Medical decision to discharge or to hospitalise the patient was evaluated at 120th min and if necessary 200th min.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Oxygen was given to patients with SaO<span class="elsevierStyleInf">2</span><span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>95%. If the patient received oxygen prior to SaO<span class="elsevierStyleInf">2</span> measurement, oxygen treatment was discontinued 10<span class="elsevierStyleHsp" style=""></span>min before.</p><p id="par0045" class="elsevierStylePara elsevierViewall">The patients were monitored for symptoms of magnesium imbalance such as nausea, vomiting, abdominal pain, chest pain, headache, fatigue, hypotension and fever.</p><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Discharging and hospitalisation criteria</span><p id="par0050" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1.</span><p id="par0055" class="elsevierStylePara elsevierViewall">Patients who responded adequately until the end of the second hour were sent home.</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2.</span><p id="par0060" class="elsevierStylePara elsevierViewall">The ones who responded partially at the end of the second hour were treated monitoring 200th min at emergency department. They were reevaluated at 200th min and those who responded adequately were discharged, and those who responded partially were hospitalised.</p></li></ul></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Evaluation of response to treatment</span><p id="par0065" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">1.</span><p id="par0070" class="elsevierStylePara elsevierViewall">Adequate response:</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">-</span><p id="par0075" class="elsevierStylePara elsevierViewall">At least two values decrease in symptom score and MPIS ≤5.</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">-</span><p id="par0080" class="elsevierStylePara elsevierViewall">SaO<span class="elsevierStyleInf">2</span><span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>95%.</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">-</span><p id="par0085" class="elsevierStylePara elsevierViewall">Better lung aeration, no or mild wheezing, minimal strain on breathing.</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">2.</span><p id="par0090" class="elsevierStylePara elsevierViewall">Partial response:</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">-</span><p id="par0095" class="elsevierStylePara elsevierViewall">Decrease in symptom score is less than two values.</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">-</span><p id="par0100" class="elsevierStylePara elsevierViewall">SaO<span class="elsevierStyleInf">2</span> 93–95%.</p></li></ul></p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Randomisation</span><p id="par0105" class="elsevierStylePara elsevierViewall">Patients were assigned consecutively to the control or intervention group based on a stratified randomisation procedure.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Statistical analysis</span><p id="par0110" class="elsevierStylePara elsevierViewall">For the statistical analysis on the evaluation of the data obtained in this study, SPSS (Statistical Package for Social Sciences) software package version 15.0 was used. Values for continuous variables were given as either mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>standard deviation or as median (interquartile range), based on the normality of distribution. Student <span class="elsevierStyleItalic">t</span> test was used in the comparison of normal and homogeneous distribution of the parametric values. Chi-square and Mann–Whitney <span class="elsevierStyleItalic">U</span> test were used to compare non-parametric values. Results were evaluated by accepting the 95% confidence interval and <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05 relevance level.</p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Results</span><p id="par0115" class="elsevierStylePara elsevierViewall">100 patients who attended with acute asthma exacerbation at the age of 3–15 evaluated according to inclusion criteria for the study; 54 male and 46 female patients with a mean age of 75.50<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>30.5 months, were included in the study. Patients were randomised to placebo and magnesium and the 50 patients in each group were divided into two groups. All patients enrolled in the study completed it. The demographic data of the study groups is given in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0120" class="elsevierStylePara elsevierViewall">The evaluation of patients with atopy, sensitivity to allergens, total serum immunoglobulin (Ig) E levels and percentage of eosinophil did not differ between the groups (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Primary aim</span><p id="par0125" class="elsevierStylePara elsevierViewall">The primary aim of our study is to compare MPIS values at the end of 120th min. When the patients were evaluated from this point, the mean of MPIS value at 120th min for magnesium group was 2.06<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1.4 (minimum–maximum: 0–7, median: 2, interquartile range: 1–3) while for placebo group 1.68<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1.8 (minimum–maximum: 0–8, median: 1, interquartile range: 0–2.75). The difference between the two groups was not found to be statistically significant (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.063) (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>).</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Secondary aim</span><p id="par0130" class="elsevierStylePara elsevierViewall">The secondary aim of our study is to compare the difference between hospitalisation rates of the two groups. When the patients were evaluated from this point, it was found that the number of hospitalised patients were six in both groups: six (12%) in the magnesium group and six (12%) in the placebo group. The difference of the hospitalisation rates between the groups was not statistically significant (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.999). No side effect caused by magnesium was observed in any of the patients in the study.</p></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Discussion</span><p id="par0135" class="elsevierStylePara elsevierViewall">In our study, we found that in moderate asthma exacerbation, the administration of isotonic nebulised Mg in addition to salbutamol in standard treatment does not provide any benefit compared to the standard treatment. This result is consistent with earlier studies.<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">9–11</span></a> The most comprehensive study about nebulised Mg in children with asthma was published by Colin Powell et al.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">10</span></a> In this double-blind, randomised, placebo-controlled study, the effect of nebulised magnesium sulphate in severe acute asthma exacerbations was investigated. For this purpose, 508 patients with the age of 2–16 who did not respond to standard treatment were included in the study. Patients were divided into two groups including magnesium and placebo nebulised salbutamol<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>ipratropium bromide<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>2.5<span class="elsevierStyleHsp" style=""></span>ml of magnesium sulphate (250<span class="elsevierStyleHsp" style=""></span>mmol/L, tonicity 289 milliosmole; 151<span class="elsevierStyleHsp" style=""></span>mg per dose) treatment was provided to the magnesium group three times with 20<span class="elsevierStyleHsp" style=""></span>min intervals and nebulised salbutamol<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>ipratropium bromide<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>2.5<span class="elsevierStyleHsp" style=""></span>ml of isotonic saline treatment was provided to the placebo group with 20<span class="elsevierStyleHsp" style=""></span>min intervals. Yung Asthma Severity Scores (ASS) in 60th min were compared. Average ASS was found as (4.72 [SD 1:37]) in the magnesium group and, (4.95 [SD 1:40]) in the placebo group. However, this difference was not considered as statistically significant. At the same time, it has been shown that the use of magnesium in serious exacerbation and exacerbation with short hospital admission time (fewer than 6<span class="elsevierStyleHsp" style=""></span>h) is more effective. Mahajan et al.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">9</span></a> determined whether a combination of nebulised magnesium sulphate and albuterol as a single dose adds any benefit in management of children with mild to moderate asthma when compared to nebulised albuterol with saline. They compared FEV1 values at 10 and 20<span class="elsevierStyleHsp" style=""></span>min. They found that the addition of magnesium to albuterol seemed to provide short-term benefits in children with acute exacerbations of mild to moderate asthma. In the study of Mangat et al.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">12</span></a> which includes adults and children (12–60 years of age), nebulised magnesium was compared with nebulised salbutamol 3<span class="elsevierStyleHsp" style=""></span>ml magnesium sulphate (95<span class="elsevierStyleHsp" style=""></span>mg) was given to the magnesium group and 3<span class="elsevierStyleHsp" style=""></span>ml salbutamol was given to the salbutamol group. 100<span class="elsevierStyleHsp" style=""></span>mg IV hydrocortisone was given to each patient. PEF values at the end of 2<span class="elsevierStyleHsp" style=""></span>h were compared and any superior bronchodilator effect of magnesium to salbutamol was not been demonstrated. These results for children were similar with studies in adults.<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">14,15</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">The second result in our study is that magnesium which was added to salbutamol had no effect on hospitalisation. These results are also consistent with previous studies.<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">10–12</span></a> The recent study published by Alansari et al.,<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">11</span></a> stated that no difference has been found between patients receiving and not receiving nebulised Mg in addition to standard treatment.</p><p id="par0145" class="elsevierStylePara elsevierViewall">Even though magnesium has a bronchodilator effect, there may be a few reasons for the lack of clinical benefit of adding nebulised salbutamol in patients with asthma exacerbation. Firstly, magnesium has a bronchodilator effect in a short term as nebulised. The study in which Meral et al.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">16</span></a> examined the effect of nebulised magnesium investigated that bronchodilator effect of Mg lasts 1<span class="elsevierStyleHsp" style=""></span>h while salbutamol's effect lasts 6<span class="elsevierStyleHsp" style=""></span>h. As mentioned above, Mahajan et al.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">9</span></a> found that adding nebulised Mg in mild to moderate asthma exacerbation in addition to albuterol provides short-term benefits. Wang et al.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">17</span></a> have investigated the effect of inhaled magnesium on bronchial hyperresponsiveness in children. Patients in the study including 84 children were divided into three groups; albuterol group, albuterol<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>magnesium group and magnesium group. Nebulised acetylcholine was given to all patients and then patients were treated in accordance with their group and their FEV1 values in 10th and 20th min were compared. As a result, a significant improvement in FEV1 was seen in each of the three groups, but more significant improvement in FEV1 on albuterol and magnesium<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>albuterol groups was achieved when compared to the magnesium group. Consequently, it is thought that magnesium has a bronchodilator effect; however it does not provide any additional benefit as adjuvant treatment. Secondly, Mg can be used in low concentrations. The concentration of nebulised magnesium to be used in asthma exacerbation is not clear. In GINA 2015, it is stated that isotonic solutions can be used.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">1</span></a> The bronchodilator effect of nebulised magnesium has already been shown to be dose-dependent.<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">18</span></a> As hypertonic solutions could lead to bronchoconstriction in asthmatics, we used isotonic solution in our study. While Mg is used in doses as high as 40–50<span class="elsevierStyleHsp" style=""></span>mg/kg (maximum 2<span class="elsevierStyleHsp" style=""></span>g) in IV administration, it is used in 151<span class="elsevierStyleHsp" style=""></span>mg/2.5<span class="elsevierStyleHsp" style=""></span>ml dose in nebulised solutions to be isotonic. But Hill et al.<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">18</span></a> found that nebulised hypertonic Mg solutions deteriorated lung functions. Therefore, high concentrations of Mg should be avoided.</p><p id="par0150" class="elsevierStylePara elsevierViewall">There are several limitations to our study. Firstly, we could not evaluate the pulmonary function tests of the patients. Furthermore, because of being a cross-sectional study, our other shortcoming is the limited number of patients. Despite these shortcomings, the results of our study are important in terms of removing the deficiency on this subject in the literature.</p><p id="par0155" class="elsevierStylePara elsevierViewall">In conclusion, in our study, the use of nebulised magnesium sulphate in moderate asthma exacerbation as adjuvant treatment did not show superiority to standard treatment. Also, we did not detect any difference in terms of hospitalisation. In spite of being a safe drug, we think that the addition of nebulised isotonic magnesium to salbutamol as adjuvant in moderate asthma exacerbation does not provide any benefits. But in larger groups of patients, studies with the use of non-irritant and higher doses of nebulised magnesium including severe asthma exacerbation may change the results in favour of magnesium.</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Ethical disclosures</span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Confidentiality of data</span><p id="par0160" class="elsevierStylePara elsevierViewall">The authors declare that they have followed the protocols of their work centre on the publication of patient data and that all the patients included in the study have received sufficient information and have given their informed consent in writing to participate in that study.</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Right to privacy and informed consent</span><p id="par0165" class="elsevierStylePara elsevierViewall">The authors have obtained the informed consent of the patients and/or subjects mentioned in the article. The author for correspondence is in possession of this document.</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Protection of human subjects and animals in research</span><p id="par0170" class="elsevierStylePara elsevierViewall">The authors declare that the procedures followed were in accordance with the regulations of the responsible Clinical Research Ethics Committee and in accordance with those of the World Medical Association and the Helsinki Declaration.</p></span></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Financial support</span><p id="par0175" class="elsevierStylePara elsevierViewall">This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Conflict of interest</span><p id="par0180" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflict of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:10 [ 0 => array:3 [ "identificador" => "xres802967" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec801309" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 3 => array:3 [ "identificador" => "sec0010" "titulo" => "Methods" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Study design" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Study population" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Study interventions" ] 3 => array:3 [ "identificador" => "sec0030" "titulo" => "Clinical evaluation" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0035" "titulo" => "Discharging and hospitalisation criteria" ] 1 => array:2 [ "identificador" => "sec0040" "titulo" => "Evaluation of response to treatment" ] ] ] 4 => array:2 [ "identificador" => "sec0045" "titulo" => "Randomisation" ] 5 => array:2 [ "identificador" => "sec0050" "titulo" => "Statistical analysis" ] ] ] 4 => array:3 [ "identificador" => "sec0055" "titulo" => "Results" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0060" "titulo" => "Primary aim" ] 1 => array:2 [ "identificador" => "sec0065" "titulo" => "Secondary aim" ] ] ] 5 => array:2 [ "identificador" => "sec0070" "titulo" => "Discussion" ] 6 => array:3 [ "identificador" => "sec0075" "titulo" => "Ethical disclosures" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0080" "titulo" => "Confidentiality of data" ] 1 => array:2 [ "identificador" => "sec0085" "titulo" => "Right to privacy and informed consent" ] 2 => array:2 [ "identificador" => "sec0090" "titulo" => "Protection of human subjects and animals in research" ] ] ] 7 => array:2 [ "identificador" => "sec0095" "titulo" => "Financial support" ] 8 => array:2 [ "identificador" => "sec0100" "titulo" => "Conflict of interest" ] 9 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-12-11" "fechaAceptado" => "2016-10-31" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec801309" "palabras" => array:4 [ 0 => "Adjuvant treatment" 1 => "Asthma exacerbations" 2 => "Childhood" 3 => "Nebulised magnesium sulphate" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">After the bronchodilator effect of magnesium was shown, the use of magnesium in treatment of asthma exacerbations became common. With the results of recent studies, the use of intravenous magnesium in severe asthma exacerbations took its place. We aimed to examine the effects of adding isotonic magnesium sulphate instead of isotonic saline into nebulised salbutamol on the Modified Pulmonary Index Score (MPIS) and the hospitalisation rate in moderate asthma exacerbations.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Our study population included 100 children age between 3 and 15 years with asthma admitted to emergency department due to moderate asthma exacerbations. The patients were randomised to placebo or magnesium, with 50 patients in each arm. All patients received 1<span class="elsevierStyleHsp" style=""></span>mg/kg of systemic methylprednisolone at the beginning of treatment and thereafter received either nebulised salbutamol (0.15<span class="elsevierStyleHsp" style=""></span>mg/kg/dose) and 1<span class="elsevierStyleHsp" style=""></span>ml magnesium sulphate (15%)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>1.5<span class="elsevierStyleHsp" style=""></span>ml isotonic saline on three occasions at roughly 20<span class="elsevierStyleHsp" style=""></span>min intervals (Magnesium group) or nebulised salbutamol (0.15<span class="elsevierStyleHsp" style=""></span>mg/kg/dose) and 2.5<span class="elsevierStyleHsp" style=""></span>ml isotonic saline mixture on three occasions at roughly 20<span class="elsevierStyleHsp" style=""></span>min intervals (Placebo group). The MPIS of patients on 0th min, 20th min, 40th and 120th min were calculated and compared. The primary outcome was to compare MPIS values at the end of 120th min.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Both groups have similar demographic, allergic characteristics and baseline MPIS scores. When the MPIS scores in the 120th min and admission rates in the 200th min, there was no significant difference between the two groups.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">The use of nebulised magnesium sulphate in moderate asthma exacerbation as adjuvant treatment showed no benefit to standard treatment in our study.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] ] "multimedia" => array:4 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2818 "Ancho" => 2667 "Tamanyo" => 431283 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Study protocol.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1181 "Ancho" => 1463 "Tamanyo" => 88838 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">The change of MPIS between the two groups with respect to time.</p>" ] ] 2 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">PED: Paediatric Emergency Department, URTI: Upper respiratory tract infection.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Magnesium group (<span class="elsevierStyleItalic">n</span>: 50) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Placebo group (<span class="elsevierStyleItalic">n</span>: 50) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Age (months)<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">†</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">76.06<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27.33 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">74.96<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>33.65 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.858 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Gender (M/F) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25/25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29/21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.547 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">The number of exacerbation in the last 1 year<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 (1–4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 (2–4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.638 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">The number of applications to PED in the last 1 year<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 (1–8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 (1–7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.638 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">The number of hospitalisations in the last 1 year<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0 (0–2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0 (0–1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.999 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">URTI prior to exacerbation, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">36 (72) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">39 (78) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.645 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Asthma in the family, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">19 (38) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">18 (36) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.999 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Exposure to smoke, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">28 (56) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25 (50) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.689 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Modified Pulmonary Index Score at 0th min<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8 (7–8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 (7–9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.316 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1347693.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "†" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>SD.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Median (interquartile range).</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Comparison of the demographic features of study population.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Magnesium group (<span class="elsevierStyleItalic">n</span>: 50) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Placebo group (<span class="elsevierStyleItalic">n</span>: 50) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Atopy, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">38 (76) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">35 (70) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.635 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sensitivity to house dust mite, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">36 (72) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">30 (60) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.482 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sensitivity to pollen, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9 (18) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9 (18) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.999 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sensitivity to dander, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8 (16) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 (8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.357 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sensitivity to moulds, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 (4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 (2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.999 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sensitivity to cockroach, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 (6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 (6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.999 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Serum total immunoglobulin E IU/ml<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">†</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">539.2<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1014.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">352.1<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>474.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.125 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Percentage of eosinophils \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5.6<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>7.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.8<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>3.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.273 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1347694.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "†" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>SD.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Comparison of laboratory parameters between groups.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:18 [ 0 => array:3 [ "identificador" => "bib0095" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global strategy for asthma management and prevention" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Global Initiative for Asthma" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "Updated May 2015" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0100" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Magnesium: physiology and pharmacology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "W.J. Fawcet" 1 => "E.J. Haxby" 2 => "D.A. Male" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Anaesth" "fecha" => "1999" "volumen" => "83" "paginaInicial" => "302" "paginaFinal" => "320" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10618948" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0105" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of magnesium chloride on rabbit bronchial smooth muscle" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "W.H. Spivey" 1 => "E.M. Skobeloff" 2 => "R.M. Levin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Emerg Med" "fecha" => "1990" "volumen" => "19" "paginaInicial" => "1107" "paginaFinal" => "1112" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1977337" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0110" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "L-type calcium channels are involved in mediating the anti-inflammatory effects of magnesium sulphate" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C.Y. Lin" 1 => "P.S. Tsai" 2 => "Y.C. Hung" 3 => "C.J. Huang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/bja/aep336" "Revista" => array:6 [ "tituloSerie" => "Br J Anaesth" "fecha" => "2010" "volumen" => "104" "paginaInicial" => "44" "paginaFinal" => "51" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19933511" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0115" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of magnesium deficiency on mast cells and urinary histamine in rats" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "P. Bois" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Exp Pathol" "fecha" => "1963" "volumen" => "44" "paginaInicial" => "151" "paginaFinal" => "155" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/13968527" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0120" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of inhaled MgSO<span class="elsevierStyleInf">4</span> on FEV1 and PEF in children with asthma induced by acetylcholine: a randomized controlled clinical trail of 330 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y.X. Sun" 1 => "C.H. Gong" 2 => "S. Liu" 3 => "X.P. Yuan" 4 => "L.J. Yin" 5 => "L. Yan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/tropej/fmt099" "Revista" => array:6 [ "tituloSerie" => "J Trop Pediatr" "fecha" => "2014" "volumen" => "60" "paginaInicial" => "141" "paginaFinal" => "147" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24343824" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0125" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Magnesium as a relaxing factor of airway smooth muscles" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K.I. Gourgoulianis" 1 => "G. Chatziparasidis" 2 => "A. Chatziefthimiou" 3 => "P.A. Molyvdas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/089426801316970259" "Revista" => array:6 [ "tituloSerie" => "J Aerosol Med" "fecha" => "2001" "volumen" => "14" "paginaInicial" => "301" "paginaFinal" => "307" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11693841" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0130" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inhaled magnesium sulfate in the treatment of acute asthma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Powell" 1 => "K. Dwan" 2 => "S.J. Milan" 3 => "R. Beasley" 4 => "R. Hughes" 5 => "J.A. Knopp-Sihota" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/14651858.CD003898.pub5" "Revista" => array:5 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2012" "volumen" => "12" "paginaInicial" => "CD003898" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23235599" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0135" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of nebulized magnesium sulfate plus albuterol to nebulized albuterol plus saline in children with acute exacerbations of mild to moderate asthma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P. Mahajan" 1 => "D. Haritos" 2 => "N. Rosenberg" 3 => "R. Thomas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jemermed.2004.02.006" "Revista" => array:6 [ "tituloSerie" => "J Emerg Med" "fecha" => "2004" "volumen" => "27" "paginaInicial" => "21" "paginaFinal" => "25" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15219299" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0140" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Powell" 1 => "R. Kolamunnage-Dona" 2 => "J. Lowe" 3 => "A. Boland" 4 => "S. Petrou" 5 => "I. Doull" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2213-2600(13)70037-7" "Revista" => array:6 [ "tituloSerie" => "Lancet Respir Med" "fecha" => "2013" "volumen" => "1" "paginaInicial" => "301" "paginaFinal" => "308" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24429155" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0145" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nebulized magnesium for moderate and severe pediatric asthma: a randomized trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "K. Alansari" 1 => "W. Ahmed" 2 => "B.L. Davidson" 3 => "M. Alamri" 4 => "I. Zakaria" 5 => "M. Alrifaai" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ppul.23158" "Revista" => array:6 [ "tituloSerie" => "Pediatr Pulmonol" "fecha" => "2015" "volumen" => "50" "paginaInicial" => "1191" "paginaFinal" => "1199" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25652104" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0150" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nebulized magnesium sulphate versus nebulized salbutamol in acute bronchial asthma: a clinical trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "H.S. Mangat" 1 => "G.A. D'Souza" 2 => "M.S. Jacob" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "1998" "volumen" => "12" "paginaInicial" => "341" "paginaFinal" => "344" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9727782" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0155" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A modified pulmonary index score with predictive value for pediatric asthma exacerbations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C.L. Carroll" 1 => "A.K. Sekaran" 2 => "T.J. Lerer" 3 => "C.M. Schramm" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1081-1206(10)60987-8" "Revista" => array:6 [ "tituloSerie" => "Ann Allergy Asthma Immunol" "fecha" => "2005" "volumen" => "94" "paginaInicial" => "355" "paginaFinal" => "359" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15801246" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0160" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized clinical trial of magnesium sulphate as a vehicle for nebulized salbutamol in the treatment of moderate to severe asthma exacerbations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "N. Kokturk" 1 => "H. Turktas" 2 => "P. Kara" 3 => "S. Mullaoglu" 4 => "F. Yilmaz" 5 => "A. Karamercan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pupt.2005.03.003" "Revista" => array:6 [ "tituloSerie" => "Pulm Pharmacol Ther" "fecha" => "2005" "volumen" => "18" "paginaInicial" => "416" "paginaFinal" => "421" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15953743" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0165" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O. Bessmertny" 1 => "R.V. DiGregorio" 2 => "H. Cohen" 3 => "E. Becker" 4 => "D. Looney" 5 => "J. Golden" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Emerg Med" "fecha" => "2002" "volumen" => "39" "paginaInicial" => "585" "paginaFinal" => "591" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12023699" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0170" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inhalation therapy with magnesium sulfate and salbutamol sulfate in bronchial asthma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Meral" 1 => "M. Coker" 2 => "R. Tanaç" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Turk J Pediatr" "fecha" => "1996" "volumen" => "38" "paginaInicial" => "169" "paginaFinal" => "175" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8701480" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0175" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of inhaled magnesium sulfate on bronchial hyperresponsiveness" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Wang" 1 => "Y. Xiong" 2 => "C. Gong" 3 => "L. Yin" 4 => "L. Yan" 5 => "X. Yuan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12098-014-1476-6" "Revista" => array:6 [ "tituloSerie" => "Indian J Pediatr" "fecha" => "2015" "volumen" => "82" "paginaInicial" => "321" "paginaFinal" => "327" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24916134" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0180" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dose–response relationship and time-course of the effect of inhaled magnesium sulphate on airflow in normal and asthmatic subjects" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Hill" 1 => "J. Britton" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Clin Pharmacol" "fecha" => "1995" "volumen" => "40" "paginaInicial" => "539" "paginaFinal" => "544" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8703659" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/03010546/0000004500000002/v1_201702200044/S0301054616301562/v1_201702200044/en/main.assets" "Apartado" => array:4 [ "identificador" => "5554" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/03010546/0000004500000002/v1_201702200044/S0301054616301562/v1_201702200044/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0301054616301562?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 31 | 0 | 31 |
2024 October | 269 | 16 | 285 |
2024 September | 322 | 20 | 342 |
2024 August | 268 | 17 | 285 |
2024 July | 282 | 12 | 294 |
2024 June | 265 | 8 | 273 |
2024 May | 312 | 10 | 322 |
2024 April | 254 | 15 | 269 |
2024 March | 353 | 14 | 367 |
2024 February | 406 | 27 | 433 |
2024 January | 474 | 29 | 503 |
2023 December | 443 | 46 | 489 |
2023 November | 409 | 49 | 458 |
2023 October | 355 | 26 | 381 |
2023 September | 252 | 30 | 282 |
2023 August | 196 | 16 | 212 |
2023 July | 237 | 31 | 268 |
2023 June | 182 | 11 | 193 |
2023 May | 220 | 17 | 237 |
2023 April | 190 | 15 | 205 |
2023 March | 212 | 16 | 228 |
2023 February | 118 | 12 | 130 |
2023 January | 158 | 21 | 179 |
2022 December | 174 | 28 | 202 |
2022 November | 119 | 14 | 133 |
2022 October | 149 | 30 | 179 |
2022 September | 116 | 25 | 141 |
2022 August | 123 | 20 | 143 |
2022 July | 102 | 20 | 122 |
2022 June | 111 | 15 | 126 |
2022 May | 117 | 21 | 138 |
2022 April | 141 | 13 | 154 |
2022 March | 261 | 26 | 287 |
2022 February | 232 | 12 | 244 |
2022 January | 229 | 15 | 244 |
2021 December | 141 | 24 | 165 |
2021 November | 169 | 28 | 197 |
2021 October | 93 | 17 | 110 |
2021 September | 82 | 13 | 95 |
2021 August | 88 | 9 | 97 |
2021 July | 53 | 12 | 65 |
2021 June | 58 | 12 | 70 |
2021 May | 67 | 29 | 96 |
2021 April | 110 | 42 | 152 |
2021 March | 61 | 25 | 86 |
2021 February | 27 | 17 | 44 |
2021 January | 33 | 12 | 45 |
2020 December | 12 | 0 | 12 |
2020 November | 0 | 1 | 1 |
2020 October | 1 | 0 | 1 |
2020 July | 0 | 4 | 4 |
2020 April | 0 | 2 | 2 |
2020 January | 0 | 4 | 4 |
2019 December | 0 | 3 | 3 |
2019 November | 0 | 2 | 2 |
2019 October | 0 | 1 | 1 |
2019 August | 0 | 1 | 1 |
2019 May | 0 | 15 | 15 |
2018 February | 14 | 8 | 22 |
2018 January | 13 | 12 | 25 |
2017 December | 1 | 3 | 4 |
2017 June | 1 | 0 | 1 |
2017 March | 5 | 0 | 5 |
2017 February | 3 | 2 | 5 |